Safety and Tolerability of Frovatriptan to Prevention of Menstrually Associated Migraine (MAM) Headaches
Status:
Completed
Trial end date:
2005-06-01
Target enrollment:
Participant gender:
Summary
In this open-label, multi-center study, patients were treated with frovatriptan for a maximum
of 12 perimenstrual periods (PMPs). For each PMP, dosing commenced 2 days before the
anticipated onset of the menstrual migraine (MM) headache and continued for a total of 6
days. Patients were to take a loading dose of frovatriptan 5 mg (two tablets) twice daily on
Day 1, followed by frovatriptan 2.5 mg twice daily on Days 2-6. During the study, patients
were to visit the study site a total of 6 times. Efficacy and/or safety assessments were
performed at each visit.